KinetiSol® is based on a commercial plastics compounding process and was developed by DisperSol into a cGMP-compliant pharmaceutical technology. The KinetiSol® pharmaceutical manufacturing process can be run from kiloton-commercial scale down to sub-10 gram batch sizes to accommodate the material-sparing needs of early drug development.
WHY USE KINETISOL ?
KinetiSol® Fits In-Line with Existing Manufacturing Operations
KinetiSol® is a new unit operation for pharmaceutical manufacturing; however, the operations upstream and downstream of the KinetiSol® compounder are conventional. The amorphous powder intermediate resulting from the KinetiSol® process train can be utilized as a powder for constitution, or can be further processed into any conventional oral dosage form.